BioSpace News Archive

Pharm Country

PAVmed Announces Closing of Firm Commitment Common Stock Offering

PAVmed announced underwritten public offering of 2,415,278 shares of its common stock at a public offering price of $1.80 per share.

January 23, 2018
·
4 min read
Biotech Beach

Aerie Pharmaceuticals Announces Public Offering of Common Stock

Aerie today announced that it has commenced a registered underwritten public offering of $75 million of shares of its common stock.

January 23, 2018
·
3 min read
Genetown

Ultivue Inc. Announces Completion of its Series B Financing

Ultivue Inc. announced today that it has closed a $20 million Series B funding round led by existing investor ARCH Venture Partners.

January 23, 2018
·
2 min read
Business

Corindus Announces Preliminary Fourth Quarter and Full Year 2017 Revenue

Preliminary and unaudited revenue for fourth quarter 2017 is expected to be between $4.0 million and $4.2 million..

January 23, 2018
·
5 min read
Genetown

Corindus to Co-Sponsor Courses at Multiple Leading Healthcare Institutions on Value-based Interventional Procedural Training

Corindus announced it will co-sponsor courses at multiple leading hospitals to educate interventional cardiologists on transradial access techniques and robotic-assisted vascular interventions.

January 23, 2018
·
7 min read
Policy

Mezzion Wins Jurisdiction Fight Against Dr. Reddy’s in New Jersey State Court

In the New Jersey State action, Mezzion has generally alleged that Dr. Reddy’s perpetrated fraud on Mezzion by concealing from Mezzion significant deficiencies in its FDA cGMP practices and by misrepresenting its FDA compliance.

January 23, 2018
·
3 min read
Deals

Astellas Completes Acquisition of Mitobridge

By exercising the option right to acquire Mitobridge, Astellas paid $225M to acquire 100% of the equity in Mitobridge.

January 23, 2018
·
3 min read
Policy

Top Trends Impacting Biopharma Innovation Strategy in 2018

Significant risk remains for companies that cannot move quickly enough to positively impact R&D productivity and for those that encounter challenges in accessing technology and expertise that likely lie outside their organization.

January 23, 2018
·
4 min read
·
Elizabeth Iorns, BioSpace.com Contributor
Drug Development

Cellectis CEO Provides Update on UCART Programs and ‘Laser Focus’ of Company in 2018

After a brief stumble with UCART123 that resulted in a clinical hold last year, Cellectis is moving on with its study.

January 23, 2018
·
3 min read
·
Alex Keown
Biotech Bay

3 Biotechs That Have Doubled Investors’ Money in Less Than a Year

Having a stock double in value is a good thing.

January 23, 2018
·
3 min read
·
Mark Terry